Retinopatija prematuriteta- savremeni koncepti skrininga i tretmana
DOI:
https://doi.org/10.5457/ams.v47iSup%201.415Keywords:
retinopathy of prematurity, neonatal screening, prevention of blindnessAbstract
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina occurring principally in new born preterm infants.According to World Health Organisation (WHO) it stands in third place of preventable causes of blindness.The exact etiology is not completely understood and many factors appear to contribute to the pathogenesis and progression of the disease. ROP is a two-phase disease, beginning with delayed retinal vascular growth after premature birth and phase II follows when phase I-induced hypoxia releases factors to stimulate new blood vessel growth. Essential in clinical approach to ROP is ophthalmological screening. Timely screening of ROP done by ophthalmologist within a few weeks after birth can prevent blindness. Good selection of infants at high risk for the occurrence of retinopathy of prematurity, as well as timely initiation of the screening, allow the proper implementation of prevention and treatment options. The responsibility of a pediatrician is to initiate screening done by ophthalmologist and ophthalmologist’s responsibility is to properly perform screening and choose treatment options. This article highlights the modern concept of the pathophysiology, screening and treatment options for ROP.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
